11:35 AM EDT, 10/14/2025 (MT Newswires) -- Shah Capital has urged the board of Novavax ( NVAX ) to pursue a sale of the company, citing persistent underperformance, continued slipups on the rollout of its COVID-19 vaccine and timid and ineffective marketing.

In a letter to the board, Shah, which owns a 7.2% stake in Novavax ( NVAX ), cited the company's "repeated strategic missteps" and argued its vaccine assets, including the COVID/flu combo vaccine and Matrix-M adjuvant technology, would have "far greater upside potential in the hands of a large capable pharma entity."

Shah said shareholders "deserve meaningful urgent action to reverse Novavax ( NVAX )' trajectory as one of the worst-performing pharma/biotech stocks of the past decade."

Novavax ( NVAX ) did not immediately respond to MT Newswires' request for comment on the matter.

Price: 8.77, Change: +0.15, Percent Change: +1.68